国产三区视频在线观看,久久久久国产精品人妻aⅴ免费,av免费观看网

Eli Lilly Full Year 2025 Financial Report Eli Lilly Eli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
Eli Lilly 2025 H1 Report Financial statements Eli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.
Eli Lilly and Camurus Sign $870M Deal for Long-Acting Incretin Therapies Using FluidCrystal? Technology Eli Lilly Eli Lilly partners with Camurus in an $870M deal to develop long-acting incretin therapies using FluidCrystal? technology, aiming to improve treatment adherence for obesity, diabetes, and chronic diseases.
Eli Lilly Acquires SiteOne in $1B Pain Drug Deal Eli Lilly Eli Lilly has acquired SiteOne Therapeutics in a deal worth up to $1 billion to develop STC-004, a promising non-opioid NaV1.8 inhibitor for chronic pain, advancing next-gen, addiction-free pain therapies.
Lilly Challenges Medicare's Exclusion of Obesity Drugs Eli Lilly Eli Lilly challenges CMS's 2026 Medicare Part D ruling that excludes coverage for obesity drugs like Zepbound and Wegovy, citing risks to patient care and provider autonomy amid rising concerns over healthcare access and costs.
Pharma's $158B U.S. Manufacturing Surge Market Trend Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Stylus Medicine Raises $85 Million! Eli Lilly Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
Semaglutide vs Tirzepatide in Weight Loss Semaglutide A head-to-head clinical trial shows Tirzepatide significantly outperforms Semaglutide in weight loss and waist reduction among obese non-diabetic adults, with superior efficacy and comparable safety.
Eli Lilly's Q1 2025 Financial report Market Trend Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
Nuclear Medicine Titans: The Battle in a $10 Billion Market Bayer Explore how pharma giants like Novartis, Bayer, AstraZeneca, BMS, and Eli Lilly are battling for dominance in the booming $10B radiopharmaceutical market with cutting-edge therapies and strategic acquisitions.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a